DoD P&T Committee- Future Meetings of the DoD P&T Committee

The Department of Defense (DoD) Pharmacy & Therapeutics (P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. Minutes of DoD P&T Committee meetings and the Committee's charter are available on the DoD P&T Committee homepage on the TRICARE Pharmacy website.

Guidance for DoD P&T Committee member's Interaction with Industry

Click here to go to the Uniform Formulary Beneficiary Advisory Panel (BAP) homepage.

Uniform Formulary Therapeutic Conversion Example

All meetings 1998-2006 click here

2007 P&T Committee Page | 2008 P&T Committee Page | 2011 P&T Committee Page | 2012 P&T Committee Page | 2013 P&T Committee Page



DoD P&T Committee Meeting Schedule


* In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new BPAs/VARRs to replace any existing BPAs/VARRs . The government will not consider existing BPA/VARR prices in the UF evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.


Meeting Date
(click on date)
Review Type Drug Classes/New Drugs Under Review* / Information for Manufacturers**
Meeting Window for Manufacturers to give Clinical/Cost Presentations
February 2014 Class Review PULMONARY-1 AGENTS January 2014
February 2014 Class Review PEC Class: GASTROINTESTINAL-1 AGENTS January 2014
February 2014 Class Review PEC Class: PANCREATIC ENZYME AGENTS January 2014
February 2014 Designated Newly Approved Drugs MIRABREGON, FORFIVO XL, BRINTELLIX, FETZIMA, KHEDEZLA January 2014
May 2014 Class Review OSTEOPOROSIS AGENTS March/April 2014
May 2014 Class Review NASAL ALLERGY AGENTS March/April 2014
May 2014 Class Review PULMONARY-1 AGENTS March/April 2014
May 2014 Designated Newly Approved Drugs ARCAPTA, MYRBETRIQ, FARXIGA, SOVALDI, UCERIS, ELIQUIS, ZORVOLEX, QUILLIVANT XR March/April 2014
Aug 2014 Class Review MULTIPLE SCLEROSIS AGENTS
Aug 2014 Class Review TARGETED IMMUNOMODULATORY BIOLOGICS
Aug 2014 Class Review NARCOTIC ANALGESICS AND COMBINATIONS: FENTANYL
Aug 2014 Designated Newly Approved Drugs Coming Soon
Nov 2014 Class Review ONCOLOGICAL AGENTS
Nov 2014 Class Review PULMONARY ARTERIAL HYPERTENSION AGENTS
Nov 2014 Designated Newly Approved Drugs Coming Soon
Feb 2015 Class Review ACNE AGENTS
Feb 2015 Designated Newly Approved Drugs Coming Soon


Subject to Change Disclaimer

The Defense Health Agency reserves the right to change the classes, subclasses and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the Defense Health Agency and manufacturer or eligible bidder.

*/** If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

PEC Webmaster
Last updated >2/18/14

Back To Top
WARNING: Unauthorized attempts to upload information or change information on this service are strictly prohibited and may be punishable under the Computer
Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act. A Division of the Pharmaceutical Operations Directorate.